연구동향 분석

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

김범석 김동완 박진현 이정옥 김태민 이세훈 정두현 허대석 2014년

논문상세정보
인용/피인용
' Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • epidermalgrowthfactorreceptor
  • lung neoplasms
  • nomograms
  • prognosis
  • tyrosine kinase inhibitor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,801 0

0.0%

' Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors' 의 참고문헌

  • Time-dependent ROC curves for censored survival data and a diagnostic marker
    Heagerty PJ Biometrics 56 : 337 ~ 344 [2000]
  • Time-dependent ROC curves for censored survival data and a diagnostic marker
    Heagerty PJ Biometrics 56 337-344 [2000]
  • The meaning and use of the area under a receiver operating characteristic(ROC)curve
    Hanley JA Radiology 143 : 29 ~ 36 [1982]
  • The meaning and use of the area under a receiver operating characteristic (ROC) curve
    Hanley JA Radiology 143 29-36 [1982]
  • Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
    Keam B Int J Clin Oncol [2014]
  • Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
    Keam B Int J Clin Oncol - [2013]
  • Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment
    Kim ST Oncology 79 : 78 ~ 84 [2010]
  • Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment
    Kim ST Oncology 79 78-84 [2010]
  • Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
    Han SW J Clin Oncol 23 : 2493 ~ 2501 [2005]
  • Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
    Han SW J Clin Oncol 23 2493-2501 [2005]
  • Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer
    Ludovini V J Thorac Oncol 6 : 707 ~ 715 [2011]
  • Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer
    Ludovini V J Thorac Oncol 6 707-715 [2011]
  • Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation
    Pencina MJ Stat Med 23 : 2109 ~ 2123 [2004]
  • Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation
    Pencina MJ Stat Med 23 2109-2123 [2004]
  • Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
    Han SW Clin Cancer Res 12 : 2538 ~ 2544 [2006]
  • Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
    Han SW Clin Cancer Res 12 2538-2544 [2006]
  • Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
    Keam B J Cancer Res Clin Oncol 137 : 1301 ~ 1308 [2011]
  • Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
    Keam B J Cancer Res Clin Oncol 137 1301-1308 [2011]
  • New guidelines to evaluate the response to treatment in solid tumors
    Therasse P J Natl Cancer Inst 92 : 205 ~ 216 [2000]
  • New guidelines to evaluate the response to treatment in solid tumors
    Therasse P J Natl Cancer Inst 92 205-216 [2000]
  • National Cancer Institute of Canada Clinical Trials Group. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
    Florescu M J Thorac Oncol 3 : 590 ~ 598 [2008]
  • National Cancer Institute of Canada Clinical Trials Group. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
    Florescu M J Thorac Oncol 3 590-598 [2008]
  • Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
    Mitsudomi T J Clin Oncol 23 : 2513 ~ 2520 [2005]
  • Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
    Mitsudomi T J Clin Oncol 23 2513-2520 [2005]
  • Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
    Harrell FE Jr Stat Med 15 : 361 ~ 387 [1996]
  • Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
    Harrell FE Jr Stat Med 15 361-387 [1996]
  • Molecular changes of epidermal growth factor receptor(EGFR)and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung
    Kim YT Lung Cancer 59 : 111 ~ 118 [2008]
  • Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung
    Kim YT Lung Cancer 59 111-118 [2008]
  • How to build and interpret a nomogram for cancer prognosis
    Iasonos A J Clin Oncol 26 : 1364 ~ 1370 [2008]
  • How to build and interpret a nomogram for cancer prognosis
    Iasonos A J Clin Oncol 26 1364-1370 [2008]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 : 2380 ~ 2388 [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 2380-2388 [2010]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 : 947 ~ 957 [2009]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 947-957 [2009]
  • Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung
    Nose N Lung Cancer 71 : 350 ~ 355 [2011]
  • Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung
    Nose N Lung Cancer 71 350-355 [2011]
  • Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
    Takano T J Clin Oncol 23 : 6829 ~ 6837 [2005]
  • Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
    Takano T J Clin Oncol 23 6829-6837 [2005]
  • EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    Paez JG Science 304 1497-1500 [2004]
  • EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy
    Paez JG Science 304 : 1497 ~ 1500 [2004]
  • Discrimination and calibration in survival analysis
    Nam BH Boston University [2000]
  • Discrimination and calibration in survival analysis
    Nam BH - [2000]
  • Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment
    Chung KP Chest 141 : 420 ~ 428 [2012]
  • Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment
    Chung KP Chest 141 420-428 [2012]
  • American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
    Keedy VL J Clin Oncol 29 : 2121 ~ 2127 [2011]
  • American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
    Keedy VL J Clin Oncol 29 2121-2127 [2011]
  • American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    Azzoli CG J Clin Oncol 27 : 6251 ~ 6266 [2009]
  • American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    Azzoli CG J Clin Oncol 27 6251-6266 [2009]
  • Activating mutationsin the epidermal growth factor receptor underlying responsivenessof non-small-cell lung cancer to gefitinib
    Lynch TJ. N Engl J Med 350 : 2129 ~ 2139 [2004]
  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib
    Lynch TJ N Engl J Med 350 2129-2139 [2004]